Allylescaline

4-allyloxy-3,5-dimethoxyphenethylamine

6Node page

what any key link opens

psx:substance/allylescaline/section/neuroscience.full@1

sectionreferenced by edges — no row of its own

derived from · upstream

informed_byClaim in neuroscience — inconclusivepsx:substance/allylescaline/claim/fa1359ac-e1bc-4f5a-a5f1-9d711772b031
informed_byClaim in neuroscience — inconclusivepsx:substance/allylescaline/claim/8c8597f3-3a51-40a8-9731-53b42bdc91b3
informed_byClaim in neuroscience — supportedpsx:substance/allylescaline/claim/7257f5cb-5238-4598-8e34-fee4edfef1f4
informed_byClaim in neuroscience — supportedpsx:substance/allylescaline/claim/17796e68-bdb5-40a6-8950-58ae86939f85

feeds · downstream

none recorded

psx:substance/allylescaline/section/neuroscience.full@1
├─ informed_by  claim/fa1359ac-e1bc-4f5a-a5f1-9d711772b031  Claim in neuroscience — inconclusive  working
├─ informed_by  claim/8c8597f3-3a51-40a8-9731-53b42bdc91b3  Claim in neuroscience — inconclusive  working
├─ informed_by  claim/7257f5cb-5238-4598-8e34-fee4edfef1f4  Claim in neuroscience — supported
├─ informed_by  claim/17796e68-bdb5-40a6-8950-58ae86939f85  Claim in neuroscience — supported
  ├─ used  src/pmid:14761703  Hallucinogens
      ├─ used  src/url:64fe93aafb2f5b59  Leminger's Scalines
      ├─ used  src/url:20b4e419263036eb  Allylescaline - Wikipedia
      ├─ used  src/url:cff8d02627d95cc3  Allylescaline (hydrochloride) product entry
      ├─ used  src/doi:10.1021/acschemneuro.2c00170  Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
      ├─ used  src/doi:10.16889/isomerdesign-1  PeakAL: Protons I Have Known and Loved — NMR spectra of psychedelic phenylethanamines including TMA-2
      ├─ used  src/url:1a18d8cbc0757c2b  Allylescaline compound entry
      ├─ used  src/url:263aeb3871e96b0c  Allylescaline compound entry (PiHKAL database)
      ├─ used  src/pmid:9301661  Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives
      ├─ used  src/pmid:16821786  C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor
      ├─ used  src/doi:10.1007/s40262-025-01544-x  Pharmacokinetics, Pharmacodynamics, and Urinary Recovery of Oral Mescaline Hydrochloride in Healthy Participants
      ├─ used  src/doi:10.1002/dta.2031  Characterization of the hepatic cytochrome P450 enzymes involved in the metabolism of 25I-NBOMe and 25I-NBOH
      ├─ used  src/doi:10.3390/ijms27073081  The Ethnopharmacological Use of Mescaline for Psychiatric Disorders: A Systematic Review
      ├─ used  src/doi:10.1007/s13181-013-0295-x  2C or Not 2C: Phenethylamine Designer Drug Review
      ├─ used  src/pmid:1969270  Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain
      ├─ used  src/doi:10.1007/s00204-020-02693-7  Designer drugs: mechanism of action and adverse effects
      ├─ derived_from  gen/31867516-095a-4c7a-a1f9-44e83641e1c2  Generation — pipeline-v5
      └─ generated_by  pub/e3b362e4-ba92-4242-bbc4-dbcb3bccca50  Publication — backfill
    ├─ used  version/1  Revision 1
    ├─ used  claim/400a8228-2cdf-4768-8c6e-6e5a81cb6672  Claim in receptor-pharmacology — inconclusive  working
    ├─ used  claim/eea41634-2bcd-414c-a537-fef2f94003cf  Claim in summary — inconclusive  working
    ├─ used  claim/4a1c1d4c-206c-40f0-96aa-53da18cbb1db  Claim in summary — inconclusive  working
    ├─ used  claim/d279c07d-c2bf-4c55-a3b7-5a52910e722b  Claim in pharmacology — inconclusive  working
    ├─ used  claim/6305c8cd-842c-4c86-908d-51444ac86e62  Claim in pharmacology — inconclusive  working
    ├─ used  claim/385ce8b5-6846-4cdd-8d79-19123bc9024d  Claim in safety — inconclusive  working
    ├─ used  claim/d2507ab0-c886-475a-b854-dd922143fc75  Claim in safety — inconclusive  working
    ├─ used  claim/260f7a1f-3cc2-4b50-af6a-dd327014c528  Claim in summary — supported
    ├─ used  claim/36a06ced-21da-4458-b4fb-d813161b2687  Claim in summary — partially_supported
    ├─ used  claim/84114eb2-8392-41b4-b4e7-4292d94278a2  Claim in pharmacology — supported
    ├─ used  claim/751fbf53-ad16-44ec-9fc6-64a41a6fcd45  Claim in pharmacology — supported
    ├─ used  claim/5571db3b-4b26-4a26-ad2b-a232a5ea351c  Claim in safety — supported
    ├─ used  claim/7790758b-a26f-4faa-9827-960bb57b8087  Claim in safety — supported
    ├─ used  claim/bf14f4d6-f42a-4f40-8698-c28501ac1b8d  Claim in receptor-pharmacology — inconclusive  working
      ├─ derived_from  issue/notice@64878b43a1d2  Issued notice
      ├─ derived_from  issue/info_card@7fe14761de26  Issued info_card
      ├─ derived_from  issue/emergency@3f0909c25c71  Issued emergency
      ├─ derived_from  issue/notice@53ffc98bc5c1  Issued notice
      ├─ derived_from  issue/info_card@64c9b8dc0dc5  Issued info_card
      ├─ derived_from  issue/emergency@c15c760aabf6  Issued emergency
      ├─ informed_by  section/receptor-pharmacology.full@1
      ├─ informed_by  section/summary.full@1
      ├─ informed_by  section/pharmacology.full@1
      └─ informed_by  section/safety.full@1
… closure truncated at 200 nodes

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

167 with DOI

5 strong · 6 moderate · 5 weak

Compilations

12026-05-11T05:02:28.259Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

29last ruled 2026-06-04

0 awaiting a ruling

Issued documents

62026-10-19T20:30:31.121Z

notice · info card · emergency

Searches

213 with no results

queries and counts on the build

Claims checked

6424 supported

24 supported · 40 not

Correspondence

0received

consent field ships in Phase 4

Edges

211

derivations recorded for this entity

Complete over 16 sources, 1 compilation, and 29 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/allylescaline/archive

2Build

one panel per compilation run

generation run 2026-05-11

53 min completedmodel pipeline-v5plan not recordedrun/906952a8…

Selection

results seen143

selected by the model28

consumed as sources16

Verification

claims checked64

supported22

partially supported2

not supported0

inconclusive40

record
seen / partial
working

The model's own caveats

4 further caveats recorded as free text — readable on the working page

Reproduce

inputs: 16 source keys (listed under Sources)
plan: not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model: pipeline-v5
streams: none — agent transcripts are persisted from 2026-09 onward

21 searches — query, source, results, what was kept and why

21 searches for this run
#	source	query	seen	kept	rationale
1	ClinicalTrials.gov · absence	allylescaline	0	0	—
2	WebSearch · absence	allylescaline forensic toxicology case report adverse effects intoxication	0	0	—
3	PubMed	allylescaline phenethylamine psychedelic	15	0	—
4	PubMed	phenethylamine serotonin 2A receptor agonist hallucinogen potency drug discrimination	3	2	Relevant for phenethylamine 5-HT2A pharmacology context.
5	OpenAlex	PiHKAL Shulgin phenethylamine synthesis psychedelic	67	2	Relevant for 2C-series pharmacology context and designer drug classification.
6	PubChem	allylescaline	1	1	Primary chemical identity verification; all data matches brief seed data.
7	OpenAlex	allylescaline mescaline analog phenethylamine	2	2	Directly relevant: NMR characterization of mescaline analogs from grey-market samples, potentially including allylescaline.
8	WebSearch	allylescaline UK law 2017 psychoactive substances act legal status Europe Australia	10	3	Legal status across major jurisdictions confirmed.
9	Erowid	PiHKAL entry #2 AL allylescaline	1	1	Primary source for Shulgin's self-experiment data and historical attribution.
10	PubMed	mescaline analogue 3,5-dimethoxy-4-alkoxyhenethylamine receptor binding serotonin	7	2	Directly relevant to mescaline-class pharmacology and 5-HT2A receptor binding, providing important class context for allylescaline.
11	CountYourCulture/IsomerDesign	Leminger 1972 scalines allylescaline history	1	2	Essential for first-described history of allylescaline.
12	PubMed	mescaline pharmacokinetics metabolism human bioavailability oral	1	1	Most relevant PK paper for mescaline class; directly applicable to allylescaline as closest structural analog.
13	WebSearch	allylescaline PiHKAL Shulgin mescaline analog pharmacology	10	3	Key secondary sources for historical context, dosing, and effects.
14	Cayman Chemical	allylescaline hydrochloride CAS physical properties	1	2	CAS number verification and toxicity disclaimer for safety section.
15	Multiple · absence	allylescaline seed data vs published sources	0	0	Verification of brief data integrity.
16	WebSearch	allylescaline physical properties melting point solubility hydrochloride	10	2	Physical property data for chemical identity section.
17	PubMed	PMID 35900876 tolerance cross-tolerance psychedelic 5-HT2A	1	1	Directly relevant for allylescaline tolerance and cross-tolerance section.
18	WebSearch	allylescaline new psychoactive substance EMCDDA 2013 Europe	10	1	Regulatory/market history context.
19	PubMed	PMID 14761703 Nichols 2004 Hallucinogens	1	1	Canonical pharmacology reference for 5-HT2A agonist mechanism applicable to allylescaline as a phenethylamine psychedelic.
20	PubMed	PMID 41977267 mescaline ethnopharmacology psychiatric systematic review	1	1	Provides class-level adverse effect profile for mescaline directly applicable to allylescaline.
21	PubMed	PMID 1969270 LSD downregulates serotonin2 receptors	1	1	Important for mescaline-class tolerance mechanism; mescaline's tolerance mechanism may differ from indole hallucinogens.

64 claims by section — every cited sentence, checked against its source

safety22 · 8 ok

Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
The most relevant class-level safety data derives from a systematic review of mescaline across 66 studies, which identified hypertension, headache, nausea, and vomiting as the most commonly reported adverse effectssupported
Systematic review of 66 studies (10 suitable for analysis). Common AEs: hypertension, headache, nausea, vomiting. ijms27073081
The broader phenethylamine designer drug class (primarily 2C-series compounds) has been associated with hallucinations, agitation, aggression, dysphoria, hypertension, tachycardia, seizures, hyperthermia, and — in fatal cases — excited-deliriumsupported
Excited delirium common among fatalities. Sympathomimetic and serotonin toxicity presentations. s13181-013-0295-x
Five deaths attributed to 2C-series drugs appear in published literature; however, these involve the 2,5-dimethoxy substituted 2C series rather than the 3,5-dimethoxy scaline series and are not directly comparable.supported
At least 5 deaths reported; excited delirium common among fatalities. s13181-013-0295-x
Class-level risks for phenethylamine psychedelics include:supported
Hallucinogens are physiologically safe and do not produce dependence or addiction. They stimulate 5-HT2A receptors especially on neocortical pyramidal cells. pmid:14761703
Phenethylamine psychedelics, including the mescaline class, do not produce physical-dependence or addictionsupported
Hallucinogens are physiologically safe and do not produce dependence or addiction. pmid:14761703
De la Fuente Revenga et al. demonstrated tolerance in mice after a single administration of doi within 24 hours, with cross-tolerance to lsdsupported
Tolerance after single dose. Cross-tolerance between DOI and LSD. acschemneuro.2c00170
Claim in safety — inconclusiveinconclusiveworking →
Cross-tolerance: Cross-tolerance between serotonergic psychedelics acting at 5-ht2a is establishedsupported
Cross-tolerance between DOI and LSD. No cross-tolerance with non-psychedelic 5-HT2AR agonist lisuride. acschemneuro.2c00170
Claim in safety — inconclusiveinconclusiveworking →
Severe cardiovascular disease (relative): phenethylamine psychedelics produce transient sympathomimetic effects (hypertension, tachycardia)supported
Common AEs: hypertension, headache, nausea, vomiting. ijms27073081
Claim in safety — inconclusiveinconclusiveworking →

pharmacology14 · 5 ok

Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
As a 3,5-dimethoxy-4-substituted phenethylamine, allylescaline is presumed to act primarily as an agonist at serotonin 5-ht2a receptors expressed on neocortical layer V pyramidal neuronssupported
They stimulate 5-HT2A receptors especially on neocortical pyramidal cells. pmid:14761703
Activation of these receptors increases cortical glutamate release, presumably via modulation of thalamocortical afferentssupported
Activation leads to increased cortical glutamate levels presumably via presynaptic receptor-mediated release from thalamic afferents. pmid:14761703
The parent compound mescaline functions as a full agonist at 5-HT₂A receptors (ED₅₀ = 33.5 µmol/kg in drug discrimination assays)supported
Mescaline fully substituted for LSD (ED50=33.5 micromol/kg). pmid:9301661
Structure-activity relationship studies demonstrate that the 3,5-methoxy groups must remain conformationally mobile for receptor activation — conformational restriction of these groups abolishes activitysupported
Rigid mescaline analogs did not fully substitute. Results consistent with requirement for full 5-HT2A agonism for hallucinogenic activity. pmid:9301661
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
For structurally related dimethoxyphenethylamines in the NBOMe series, cyp3a4 and cyp2d6 have been identified as the principal metabolic enzymessupported
Major CYPs for 25I-NBOMe: CYP3A4 and CYP2D6. dta.2031

receptor-pharmacology6 · 1 ok

Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
5-HT₂A: Presumed primary target. Mescaline is a full agonist (ED₅₀ = 33.5 µmol/kg, rat drug discrimination). The 4-position ether modification is pharmacologically tolerated.supported
Mescaline fully substituted for LSD (ED50=33.5 micromol/kg). Results consistent with requirement for full 5-HT2A agonism for hallucinogenic activity. pmid:9301661
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

summary6 · 3 ok

Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
As a 3,5-dimethoxyphenethylamine, allylescaline is presumed to act primarily through agonism at serotonin 5-ht2a receptors on neocortical layer V pyramidal neurons, consistent with its structural classsupported
They stimulate 5-HT2A receptors especially on neocortical pyramidal cells. pmid:14761703
The compound is not expected to produce physical-dependence based on the pharmacology of its structural class. tolerance develops rapidly following single administration, consistent with 5-HT₂A receptor-mediated tachyphylaxis observed in related psychedelicspartially supported
Hallucinogens are physiologically safe and do not produce dependence or addiction. pmid:14761703
The compound is not expected to produce physical-dependence based on the pharmacology of its structural class. tolerance develops rapidly following single administration, consistent with 5-HT₂A receptor-mediated tachyphylaxis observed in related psychedelicssupported
Repeated DOI induces progressive decrease in HTR. Tolerance after single dose. DOI caused 5-HT2AR downregulation in frontal cortex. acschemneuro.2c00170

comparative-pharmacology4 · 2 ok

Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
The SAR established by Monte et al. demonstrates that structural modifications at the 4-position are tolerated provided the 3,5-dimethoxy groups retain conformational mobilitypartially supported
Rigid mescaline analogs did not fully substitute. Results consistent with requirement for full 5-HT2A agonism for hallucinogenic activity. pmid:9301661
McLean et al. confirmed that 4-position modifications modulate potency at 5-ht2a within the mescaline scaffold.supported
Conformationally restricted mescaline analogue with 3-fold higher 5-HT2A affinity/potency than mescaline. R-(+) isomer more potent. pmid:16821786

neuroscience4 · 2 ok

Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
As a presumed serotonin 2A receptor agonist, allylescaline is expected to produce its effects through mechanisms established for the psychedelic phenethylamine and tryptamine classes:supported
They stimulate 5-HT2A receptors especially on neocortical pyramidal cells. Activation leads to increased cortical glutamate levels presumably via presynaptic receptor-mediated release from thalamic afferents. pmid:14761703
Cortical glutamate release: 5-HT₂A activation triggers glutamate release from thalamocortical afferents, increasing excitatory neurotransmission in prefrontal and associative cortices.supported
Activation leads to increased cortical glutamate levels presumably via presynaptic receptor-mediated release from thalamic afferents. In vivo imaging shows hallucinogens increase prefrontal cortical metabolism. pmid:14761703

pharmacokinetic-detail4 · 1 ok

Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
For the structurally related NBOMe series of 2,5-dimethoxyphenethylamines, cyp3a4 and cyp2d6 were identified as the major metabolic enzymes via in vitro reaction phenotypingsupported
Major CYPs for 25I-NBOMe: CYP3A4 and CYP2D6. Intrinsic clearance 70.1 mL/min/kg. dta.2031

clinical-evidence2 · 1 ok

Claim in clinical-evidence — inconclusiveinconclusiveworking →
The broader mescaline class has shown preliminary therapeutic signals in depression, well-being, and substance use disorders in a systematic review encompassing 66 studies, but these findings apply to mescaline itself and cannot be extrapolated to allylescaline without dedicated investigation.supported
Systematic review of 66 studies (10 suitable for analysis). Therapeutic effects: improved depression, well-being, nicotine dependence, alcohol use, obsessions. ijms27073081

history2 · 1 ok

Claim in history — inconclusiveinconclusiveworking →
In 2015, Chapman and Avanes published ¹H NMR spectroscopic characterization of grey-market allylescaline samples obtained from North American and European vendors, confirming the structural identity of material circulating commerciallysupported
1H NMR spectra of 28 alleged psychedelic phenylethanamines from 15 grey-market internet vendors. Members from each principal phenylethanamine family analyzed...four mescaline analogues. isomerdesign-1

3Sources

16 consumed · sorted by year · feeds = sections resting on it

Sources
year	source	tier	status	feeds
2026	The Ethnopharmacological Use of Mescaline for Psychiatric Disorders: A Systematic ReviewShaw J, Yong A, Lee J, Cheng J, Andricioaei A, Wang JY, Zisman-Ilani Y, Bota R · International Journal of Molecular Sciencesdoi:10.3390/ijms27073081	strong	consumed	2 sections
2025	Pharmacokinetics, Pharmacodynamics, and Urinary Recovery of Oral Mescaline Hydrochloride in Healthy ParticipantsMueller L, Klaiber A, Ley L, Becker AM, Thomann J, Luethi D, Schmid Y, Liechti ME · Clinical Pharmacokineticsdoi:10.1007/s40262-025-01544-x	strong	consumed	2 sections
2024	Allylescaline - WikipediaWikipedia contributorsurl:20b4e419263036eb	weak	consumed	cited only
2024	Allylescaline (hydrochloride) product entryCayman Chemicalurl:cff8d02627d95cc3	weak	consumed	cited only
2024	Allylescaline compound entryPubChemurl:1a18d8cbc0757c2b	moderate	consumed	cited only
2022	Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Micede la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, Gonzalez-Maeso J · ACS Chemical Neurosciencedoi:10.1021/acschemneuro.2c00170	moderate	consumed	2 sections
2020	Designer drugs: mechanism of action and adverse effectsLuethi D, Liechti ME · Archives of Toxicologydoi:10.1007/s00204-020-02693-7	strong	consumed	1 section
2017	Characterization of the hepatic cytochrome P450 enzymes involved in the metabolism of 25I-NBOMe and 25I-NBOHNielsen LM, Holm NB, Leth-Petersen S, Kristensen JL, Olsen L, Linnet K · Drug Testing and Analysisdoi:10.1002/dta.2031	moderate	consumed	2 sections
2015	Allylescaline compound entry (PiHKAL database)IsomerDesignurl:263aeb3871e96b0c	weak	consumed	cited only
2015	PeakAL: Protons I Have Known and Loved — NMR spectra of psychedelic phenylethanamines including TMA-2Chapman SJ, Avanes AAdoi:10.16889/isomerdesign-1	weak	consumed	1 section
2013	2C or Not 2C: Phenethylamine Designer Drug ReviewDean BV, Stellpflug SJ, Burnett A, Engebretsen KM · Journal of Medical Toxicologydoi:10.1007/s13181-013-0295-x	strong	consumed	1 section
2012	Leminger's ScalinesChapman SJurl:64fe93aafb2f5b59	weak	consumed	cited only
2006	C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptorMcLean TH, Chambers JJ, Parrish JC, Braden MR, Marona-Lewicka D, Kurrasch-Orbaugh D, Nichols DE · Journal of Medicinal Chemistrypmid:16821786	moderate	consumed	3 sections
2004	HallucinogensNichols DE · Pharmacology & Therapeuticspmid:14761703	strong	consumed	5 sections
1997	Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivativesMonte AP, Waldman SR, Marona-Lewicka D, Wainscott DB, Nelson DL, Sanders-Bush E, Nichols DE · Journal of Medicinal Chemistrypmid:9301661	moderate	consumed	3 sections
1990	Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brainBuckholtz NS, Zhou DF, Freedman DX, Potter WZ · Neuropsychopharmacologypmid:1969270	moderate	consumed	1 section
—	Searched ClinicalTrials.gov for "allylescaline" — no resultsabsence		no results	—
—	Searched Multiple for "allylescaline seed data vs published sources" — no resultsabsence		no results	—
—	Searched WebSearch for "allylescaline forensic toxicology case report adverse effects intoxication" — no resultsabsence		no results	—

4Docket

one filing per activity — decisions, correspondence, reports

0012026-05-11revisionRevision 1
Initial LLM generation (v5 pipeline, wiki, prose phase)
psx:substance/allylescaline/version/1
0022026-06-04proposal27 value proposals approved together
one review action inferred from a shared reviewer and instant — the graph records one activity per proposal
27 items in this filing
- contraindication · other
- contraindication · neurological
- contraindication · cardiovascular
- contraindication · pregnancy_breastfeeding
- contraindication · neurological
- dose_tier · threshold
- dose_tier · light
- dose_tier · common
- dose_tier · strong
- dose_tier · heavy
- timeline · oral · onset
- timeline · oral · come_up
- timeline · oral · peak
- timeline · oral · resolution
- timeline · oral · afterglow
- toxicity
- dependence · full
- withdrawal
- tolerance
- dosage · oral
- duration · oral · onset
- duration · oral · come_up
- duration · oral · peak
- duration · oral · offset
- duration · oral · total
- duration · oral · aftereffects
psx:substance/allylescaline/proposal/contraindication/72506e60-e7cd-47a0-9b80-da981610180c
0032026-06-04publicationPublication — backfill
psx:substance/allylescaline/pub/e3b362e4-ba92-4242-bbc4-dbcb3bccca50

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
document	content hash	issued	from version	superseded
emergency	c15c760aabf6f0fcf5b6fc6b…	2026-10-19 20:30	Revision 1	current
info_card	64c9b8dc0dc52da11c921957…	2026-10-19 20:30	Revision 1	current
notice	53ffc98bc5c175e403d133df…	2026-10-19 20:30	Revision 1	current
emergency	3f0909c25c714d225b4bb3e3…	2026-09-04 04:28	Revision 1	superseded2026-10-19
info_card	7fe14761de2672ace8c44833…	2026-09-04 04:28	Revision 1	superseded2026-10-19
notice	64878b43a1d2932a5305f55b…	2026-09-04 04:28	Revision 1	superseded2026-10-19

Allylescaline

6Node page

derived from · upstream

feeds · downstream

1Provenance card

2Build

generation run 2026-05-11

research→

draft→

audit→

verify→

simplify→

publish

Selection

Verification

The model's own caveats

Reproduce

3Sources

4Docket

5Issued documents

research

draft

audit

verify

simplify